86472 20240104111813.0 doi 10.4103/1673-5374.270299 sideral 115320 ART-2020-115320 eng Calvo, Ana Cristina Universidad de Zaragoza (orcid)0000-0001-5193-7782 Type XIX collagen: a promising biomarker from the basement membranes 2020 Access copy available to the general public Unrestricted Among collagen members in the collagen superfamily, type XIX collagen has raised increasing interest in relation to its structural and biological roles. Type XIX collagen is a Fibril-Associated Collagen with Interrupted Triple helices member, one main subclass of collagens in this superfamily. This collagen contains a triple helix composed of three polypeptide segments aligned in parallel and it is associated with the basement membrane zone in different tissues. The molecular structure of type XIX collagen consists of five collagenous domains, COL1 to COL5, interrupted by six non-collagenous domains, NC1 to NC6. The most relevant domain by which this collagen exerts its biological roles is NC1 domain that can be cleavage enzymatically to release matricryptins, exerting anti-tumor and anti-angiogenic effect in murine and human models of cancer. Under physiological conditions, type XIX collagen expression decreases after birth in different tissues although it is necessary to keep its basal levels, mainly in skeletal muscle and hippocampal and telencephalic interneurons in brain. Notwithstanding, in amyotrophic lateral sclerosis, altered transcript expression levels show a novel biological effect of this collagen beyond its structural role in basement membranes and its anti-tumor and anti-angiogenic properties. Type XIX collagen can exert a compensatory effect to ameliorate the disease progression under neurodegenerative conditions specific to amyotrophic lateral sclerosis in transgenic SOD1G93A mice and amyotrophic lateral sclerosis patients. This novel biological role highlights its nature as prognostic biomarker of disease progression in and as promising therapeutic target, paving the way to a more precise prognosis of amyotrophic lateral sclerosis. info:eu-repo/grantAgreement/ES/FIS-FEDER/PI17-00949 info:eu-repo/semantics/openAccess by-nc-sa http://creativecommons.org/licenses/by-nc-sa/3.0/es/ 5.135 2020 NEUROSCIENCES 78 / 273 = 0.286 2020 Q2 T1 CELL BIOLOGY 78 / 195 = 0.4 2020 Q2 T2 0.93 2020 Developmental Neuroscience 2020 Q2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Moreno, Laura (orcid)0000-0002-7277-4318 Moreno, Leticia Universidad de Zaragoza (orcid)0000-0003-2436-7205 Toivonen, Janne Universidad de Zaragoza (orcid)0000-0002-7243-1737 Manzano, Raquel Universidad de Zaragoza (orcid)0000-0002-7477-8742 Molina, Nora de la Torre, Miriam Universidad de Zaragoza (orcid)0000-0002-7955-7164 Lopez, Tresa Universidad de Zaragoza (orcid)0000-0001-9802-8199 Miana-Mena, Francisco Javier Universidad de Zaragoza (orcid)0000-0001-5981-5448 Muñoz, María Jesús Zaragoza, Pilar Universidad de Zaragoza (orcid)0000-0001-5740-0185 Larrodé, Pilar Universidad de Zaragoza (orcid)0000-0001-6199-2953 García-Redondo, Alberto Osta, Rosario Universidad de Zaragoza (orcid)0000-0001-5687-6704 1001 420 Universidad de Zaragoza Dpto. Anatom.,Embri.Genét.Ani. Área Genética 1012 410 Universidad de Zaragoza Dpto. Farmac.Fisiol.y Med.L.F. Área Fisiología 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 15, 6 (2020), 988-995 NEURAL REGENERATION RESEARCH NEURAL REGENERATION RESEARCH 1673-5374 1464960 http://zaguan.unizar.es/record/86472/files/texto_completo.pdf Versión publicada 1697 http://zaguan.unizar.es/record/86472/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:86472 articulos driver 2024-01-04-11:03:22 ARTICLE